Lates News

Every AI Express News, on May 6th, Open Source Securities released a research report giving a buy rating to Renfu Medicine (600079.SH). The main reasons for the rating include: 1) the performance of each subsidiary is stable, with strong core competitiveness in anesthesia products; 2) restructuring and return to core business are steadily progressing, and the leading position in anesthesia is expected to usher in valuation repair. (Daily Economic News)